Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome
- PMID: 11684808
- DOI: 10.1159/000046288
Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome
Abstract
Shiga toxin (Stx) and lipopolysaccharide (LPS) both participate in the pathogenesis of post-diarrheal hemolytic uremic syndrome (HUS), yet little is known about the factors that modulate the host response to these toxins. We have previously shown that the baboon develops HUS if 100 ng/kg of purified Stx-1 is administered rapidly as a single bolus, but not if it is given as four 25-ng/kg doses every 12 h. We therefore used this baboon model to study the response to small intravenous doses of Stx-1, with and without the co-administration of LPS. The co-administration of two 1-mg/kg doses of LPS (given at 0 and 24 h) and four 25-ng/kg doses of Stx-1 (given at 0, 12, 24, and 36 h) resulted in HUS, but the administration of either toxin separately did not. The development of HUS was associated with a rise in urinary, but not plasma concentrations of TNF, and a rise in both urinary and plasma concentrations of IL-6 and IL-8. We speculate that LPS is not required for disease expression in the human, but that it can augment the response to otherwise subtoxic amounts of Stx and this augmentation may be mediated by LPS-induced cytokine release.
Copyright 2001 S. Karger AG, Basel
Similar articles
-
Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome.J Am Soc Nephrol. 2001 Jul;12(7):1458-1467. doi: 10.1681/ASN.V1271458. J Am Soc Nephrol. 2001. PMID: 11423574
-
von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome.Pediatr Dev Pathol. 2002 Sep-Oct;5(5):472-9. doi: 10.1007/s10024-001-0204-1. Epub 2002 Aug 29. Pediatr Dev Pathol. 2002. PMID: 12196894
-
Renal prostacyclin biosynthesis in a baboon model of Shiga toxin mediated hemolytic uremic syndrome.Nephron. 2002 Oct;92(2):363-8. doi: 10.1159/000063310. Nephron. 2002. PMID: 12218315
-
Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome.Pediatr Nephrol. 2001 Oct;16(10):823-39. doi: 10.1007/s004670100660. Pediatr Nephrol. 2001. PMID: 11605791 Review.
-
Escherichia coli Shiga toxin.J Nat Toxins. 2000 Aug;9(3):299-313. J Nat Toxins. 2000. PMID: 10994531 Review.
Cited by
-
Dexamethasone rescues neurovascular unit integrity from cell damage caused by systemic administration of shiga toxin 2 and lipopolysaccharide in mice motor cortex.PLoS One. 2013 Jul 23;8(7):e70020. doi: 10.1371/journal.pone.0070020. Print 2013. PLoS One. 2013. Retraction in: PLoS One. 2023 Dec 7;18(12):e0295781. doi: 10.1371/journal.pone.0295781. PMID: 23894578 Free PMC article. Retracted.
-
Shiga toxin pathogenesis: kidney complications and renal failure.Curr Top Microbiol Immunol. 2012;357:105-36. doi: 10.1007/82_2011_172. Curr Top Microbiol Immunol. 2012. PMID: 21983749 Free PMC article. Review.
-
Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.Infect Immun. 2008 Oct;76(10):4469-78. doi: 10.1128/IAI.00592-08. Epub 2008 Aug 11. Infect Immun. 2008. PMID: 18694970 Free PMC article.
-
Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.Blood. 2005 Dec 15;106(13):4199-209. doi: 10.1182/blood-2005-05-2111. Epub 2005 Aug 30. Blood. 2005. PMID: 16131569 Free PMC article.
-
Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.Pediatr Nephrol. 2003 Feb;18(2):92-6. doi: 10.1007/s00467-002-1035-7. Epub 2003 Jan 10. Pediatr Nephrol. 2003. PMID: 12579394
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources